Modafinil

Hypersomnia

Duke UniversitySmall moleculePhase 2Active

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 95/ 100

Competitive context

3 Active assets in the Hypersomnia cohort.

Asset / Sponsor	Phase	Rating
Solriamfetol Duke University	Phase 2	BB
Caffeine Ron Postuma	Phase 2/3	B
Melatonin Duke University	Phase 2	B
Valiloxybate XWPharma	Phase 2	CCC
.Gamma.-Hydroxybutyrate Sodium Salt Brigham and Women's Hospital	Early Phase 1	C
Gate-101 Syndeio Biosciences, Inc	Phase 1	NR

Same molecule, other indications

Modafinil is also rated in:

schizophreniaActive

BB

Indicative · Phase 4

66 / 100

schizoaffective disorderActive

BB

Indicative · Phase 4

65 / 100

sleep disorderActive

BB

Indicative · Phase 3

65 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.